Position in HLN
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$193,581
+$5,637 QoQ
Shares Held
19,339
+4.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
10 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in HLN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Ascentis Independent Advisors holds $313,173 across 19 Drug Manufacturers - Specialty & Generic names. HLN ranks #1 (61.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HLN |
Haleon plc
This page
|
19,339 | $193,581 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
305 | $40,180 | |
| 3 | ZTS |
Zoetis Inc.
|
182 | $21,512 | |
| 4 | LQDA |
Liquidia Corp
|
391 | $14,756 | |
| 5 | GTBIF |
Green Thumb Industries Inc.
|
1,210 | $7,719 | |
| 6 | VTRS |
Viatris Inc
|
571 | $7,712 | |
| 7 | CRON |
Cronos Group Inc.
|
2,451 | $6,152 | |
| 8 | ELAN |
Elanco Animal Health Inc
|
250 | $5,982 |
All Filings in HLN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $193,581 | 19,339 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $187,944 | 18,590 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $162,222 | 18,085 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $161,626 | 15,586 | Shares | Sole | 2025-07-14 | |
| 2025-03-31 | $156,624 | 15,221 | Shares | Sole | 2025-04-23 | |
| 2024-12-31 | $158,678 | 16,633 | Shares | Sole | 2025-01-24 | |
| 2024-09-30 | $39,730 | 3,756 | Shares | Sole | 2024-10-29 | |
| 2024-06-30 | $152,140 | 18,419 | Shares | Sole | 2024-07-29 | |
| 2023-12-31 | $89,846 | 10,917 | Shares | Sole | 2024-02-02 | |
| 2023-09-30 | $84,957 | 10,199 | Shares | Sole | 2023-10-20 | |
| No filing history on record for this holder in this stock. | ||||||